Home › Bronchiolitis Obliterans Syndrome › NCT07127926

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic Graft Versus Host Disease

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Male and female subjects ≥ 18 years of age with allogeneic HSCT

Exclusion Criteria:

* Receiving an investigational GVHD treatment within 28 days of study entry; (2) active acute GVHD; and (3) taking any medication known to be CYP3A4 inducers.
* Pregnancy is an exclusion criterion for stem cell transplant. Pregnant women are not included in this study. Non-viable neonates will not be included in this study. Patients with cognitive impairments will not be included in this study. Patients aged less than 18 years old will not be included.

About the study

The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).

What is being tested

• Belumosudil (drug)

Sponsor: M.D. Anderson Cancer Center · Participants: 8 · Started: Feb 9, 2026

Contact the study team

• Amin Alousi, MD · Phone: (713) 745-8613

Official record on ClinicalTrials.gov — NCT07127926

Locations in the U.S.

Conditions

• Bronchiolitis Obliterans Syndrome

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.